📣 VC round data is live. Check it out!

Natera Valuation Multiples

Discover Natera's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like GE HealthCare, Illumina, Agilent, Quest Diagnostics and more.

Natera Overview

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.


Founded

2007

HQ

United States

Employees

4.4K

Website

natera.com

Financials (LTM)

Revenue: $3B
EBITDA: ($235M)

EV

$30B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Natera Financials

Natera reported last 12-month revenue of $3B and negative EBITDA of ($235M).

In the same LTM period, Natera generated $2B in gross profit, ($235M) in EBITDA losses, and had net loss of ($214M).

Revenue (LTM)


Natera P&L

In the most recent fiscal year, Natera reported revenue of $2B and EBITDA of ($221M).

Natera is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (10%), and net margin of (9%).

See analyst estimates for Natera
LTMLast FY202320242025202620272028
Revenue$3B$2B$1B$2B$2B
Gross Profit$2B$1B$493M$1B$1B
Gross Margin65%65%46%60%65%
EBITDA($235M)($221M)($398M)($148M)($221M)
EBITDA Margin(9%)(10%)(37%)(9%)(10%)
EBIT Margin(12%)(13%)(41%)(13%)(13%)
Net Profit($214M)($208M)($435M)($190M)($208M)
Net Margin(9%)(9%)(40%)(11%)(9%)

Financial data powered by Morningstar, Inc.

Natera Stock Performance

Natera has current market cap of $31B, and enterprise value of $30B.

Market Cap Evolution


Natera's stock price is $218.81.

Natera share price decreased by 2.0% in the last 30 days, and increased by 29.5% in the last year.

Natera has an EPS (earnings per share) of $-1.45.

See more trading valuation data for Natera
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$30B$31B-2.0%-2.0%9.4%29.5%$-1.45

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Natera Valuation Multiples

Natera trades at 12.1x EV/Revenue multiple, and (129.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Natera

EV / Revenue (LTM)


Natera Financial Valuation Multiples

As of June 2, 2026, Natera has market cap of $31B and EV of $30B.

Natera has a P/E ratio of (146.2x).

LTMLast FY202320242025202620272028
EV/Revenue12.1x13.2x28.2x18.0x13.2x
EV/EBITDA(129.7x)(138.3x)(76.6x)(205.9x)(138.3x)
EV/EBIT(104.9x)(98.4x)(68.3x)(137.2x)(98.4x)
EV/Gross Profit18.7x20.4x61.9x29.8x20.4x
P/E(146.2x)(150.5x)(72.1x)(164.6x)(150.5x)
EV/FCFn/mn/m(106.5x)n/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Natera Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Natera Margins & Growth Rates

Natera grew revenue by 21% but EBITDA decreased by 14% in the last fiscal year.

In the most recent fiscal year, Natera reported gross margin of 65%, EBITDA margin of (10%), and net margin of (9%).

See estimated margins and future growth rates for Natera

Natera Margins

Last FY202420252026202720282029
Gross Margin65%60%65%65%
EBITDA Margin(10%)(9%)(10%)(7%)
EBIT Margin(13%)(13%)(13%)(9%)
Net Margin(9%)(11%)(9%)(8%)
FCF Margin3%3%3%2%

Natera Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth21%57%36%21%
Gross Profit Growth22%108%46%22%
EBITDA Growth(14%)(63%)49%(14%)
EBIT Growth(15%)(50%)39%(15%)
Net Profit Growth7%(56%)9%7%
FCF Growth(25%)(121%)30%(25%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Natera Operational KPIs

Natera's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

Natera's Rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Natera's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Natera
LTMLast FY202320242025202620272028
Rule of 4010%15%---
Bessemer Rule of X40%46%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.4M---
R&D Expenses to Revenue29%27%30%24%27%
Opex to Revenue-78%87%73%78%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Natera Competitors

Natera competitors include GE HealthCare, Illumina, Agilent, Quest Diagnostics, Labcorp, Exact Sciences, Guardant Health, Hologic, United Imaging and Roche.

Most Natera public comparables operate across Diagnostics & Genomics, Medical Imaging & Diagnostics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
GE HealthCare1.8x1.7x9.7x9.9x
Illumina6.0x5.9x18.0x21.1x
Agilent5.7x5.6x20.0x19.0x
Quest Diagnostics2.5x2.4x12.5x12.2x
Labcorp2.0x1.9x11.4x11.1x
Exact Sciences----
Guardant Health18.1x15.8x(79.9x)(87.5x)
Hologic----

This data is available for Pro users. Sign up to see all Natera competitors and their valuation data.

Start Free Trial

Natera VC Funding History

Before going public, Natera raised $110M in total equity funding, across 2 rounds.


Natera Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-15Series FPutnam Premier IT; HealthCor Partners; Jennison Associates; OrbiMed; RA Capital Management; Sequoia Capital; Sofinnova Investments$56M--
May-13Series EClaremont Creek Ventures; Founders Fund; Harmony Partners; Lightspeed Venture Partners; OrbiMed; Sequoia Capital$55M-Natera, a San Carlos, California-based developer of non-invasive prenatal genetic tests, completed a $54.6 million Series E financing round on May 1, 2013, to support the expansion and global rollout of its Panorama test, which screens for chromosomal anomalies like Down syndrome using cell-free fetal DNA from maternal blood as early as nine weeks gestation. The round was co-led by OrbiMed Advisors and Harmony Partners, with participation from existing investors including Claremont Creek Ventures, Lightspeed Venture Partners, Founders Fund, and Sequoia Capital. Panorama offered superior accuracy with no reported false positives or negatives, broader coverage, and earlier results compared to first-generation tests. The funding enabled Natera to scale its laboratory operations, sales and marketing teams to meet rising demand from OBGYN physicians and IVF centers, and pursue additional R&D including detection of triploidy and new applications of its NATUS cell-free DNA technology for oncology. Natera had launched Panorama in 2013 following its rebranding from Gene Security Network, with prior raises including $20 million in January 2012 and earlier rounds totaling smaller amounts. Partnerships with Quest Diagnostics, ARUP Laboratories, and Bio-Reference Laboratories facilitated US distribution and market penetration in the growing non-invasive prenatal testing sector. Investors highlighted Natera's strong leadership, aggressive launch strategy, and breakthrough big-data computation combined with genomic science, positioning Panorama as a leader in NIPT. The company operated a CLIA-certified lab and focused on commercial expansion amid substantial market growth in non-invasive genetic testing.

Acquisitions by Natera

Natera has acquired 1 company to date.

Last acquisition by Natera was on December 4th 2025. Natera acquired Foresight Diagnostics for $275M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Natera

Foresight Diagnostics
Description
Foresight Diagnostics is a Boulder-based developer of the RaDaR assay, a liquid biopsy test measuring minimal residual disease in blood cancers via patient-specific DNA sequencing. The platform detects circulating tumor DNA with high sensitivity for lymphoma and multiple myeloma monitoring. It has secured partnerships with pharmaceutical firms like Bristol Myers Squibb and Genentech for clinical trials. Founded in 2017 as a spinout from University of Colorado, Foresight operates CLIA-certified labs processing thousands of samples annually.
HQ CountryUnited States
HQ City
Denver, CO
Deal Date4 Dec 2025
Valuation$275M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Natera acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Natera

Natera has invested in 1 company to date.

Latest investment by Natera was on December 11th 2025. Natera invested in Myome in their Undisclosed stage round.

See VC round multiples

Latest Investments by Natera

Myome
Myome
Description
Myome is a genomics platform that sequences and analyzes whole genomes for disease risk identification. Users store data in a portable format accessible via HIPAA-compliant cloud for lifelong reuse in research matching. Processing occurs at CLIA-certified labs in the US, covering 100 million genetic variants. Founded in 2020 and based in Boston, Myome partners with 23andMe for ancestry-linked health insights.
Myome is a genomics platform that sequences and analyzes whole genomes for disease risk identification. Users store data in a portable format accessible via HIPAA-compliant cloud for lifelong reuse in research matching. Processing occurs at CLIA-certified labs in the US, covering 100 million genetic variants. Founded in 2020 and based in Boston, Myome partners with 23andMe for ancestry-linked health insights.
HQ CountryUnited StatesUnited States
HQ City
San Francisco, CA
San Francisco, CA
Deal Date11 Dec 202521 Jun 2022
RoundUndisclosed stageSeries B
Raisedundisclosed$23M
InvestorsDuquesne Family Office; Illumina; Natera; Sequoia CapitalForesite Capital; Founders Fund; Healthcare Venture Partners; HOF Capital; Natera; Norwest; Sequoia Capital; SoftBank Group
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Natera investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Natera

When was Natera founded?Natera was founded in 2007.
Where is Natera headquartered?Natera is headquartered in United States.
How many employees does Natera have?As of today, Natera has over 4K employees.
Who is the CEO of Natera?Natera's CEO is Steven Leonard Chapman.
Is Natera publicly listed?Yes, Natera is a public company listed on Nasdaq.
What is the stock symbol of Natera?Natera trades under NTRA ticker.
When did Natera go public?Natera went public in 2015.
Who are competitors of Natera?Natera main competitors include GE HealthCare, Illumina, Agilent, Quest Diagnostics, Labcorp, Exact Sciences, Guardant Health, Hologic, United Imaging, Roche.
What is the current market cap of Natera?Natera's current market cap is $31B.
What is the current revenue of Natera?Natera's last 12 months revenue is $3B.
What is the current revenue growth of Natera?Natera revenue growth (NTM/LTM) is 20%.
What is the current EV/Revenue multiple of Natera?Current revenue multiple of Natera is 12.1x.
Is Natera profitable?No, Natera is not profitable.
What is the current EBITDA of Natera?Natera has negative EBITDA and is not profitable.
What is Natera's EBITDA margin?Natera's last 12 months EBITDA margin is (9%).
What is the current EV/EBITDA multiple of Natera?Current EBITDA multiple of Natera is (129.7x).
What is the current FCF of Natera?Natera's last 12 months FCF is $12M.
What is Natera's FCF margin?Natera's last 12 months FCF margin is 0%.
What is the current EV/FCF multiple of Natera?Current FCF multiple of Natera is 2630.2x.
How many companies Natera has acquired to date?As of June 2026, Natera has acquired 1 company.
What was the largest acquisition by Natera?$275M acquisition of Foresight Diagnostics on 4th December 2025 was the largest M&A Natera has done to date.
What companies Natera acquired?Natera acquired Foresight Diagnostics.
In how many companies Natera has invested to date?As of June 2026, Natera has invested in 1 company.
What was the last Natera investment?On 11th December 2025 Natera invested in Myome, participating in a Undisclosed stage round, alongside Duquesne Family Office, Illumina, and Sequoia Capital.
In what companies Natera invested in?Natera invested in Myome.

See public comps similar to Natera

Lists including Natera

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial